Simultaneous quantification of buprenorphine, norbuprenorphine, buprenorphine-glucuronide and norbuprenorphine-glucuronide in human umbilical cord by liquid chromatography tandem mass spectrometry

被引:22
作者
Concheiro, Marta [1 ]
Shakleya, Diaa M. [1 ]
Huestis, Marilyn A. [1 ]
机构
[1] NIDA, Biomed Res Ctr, Chem & Drug Metab Sect, Intramural Res Program,NIH, Baltimore, MD 21224 USA
关键词
Umbilical cord; Buprenorphine; LCMS; Ion trap; HUMAN PLASMA; METABOLITE NORBUPRENORPHINE; DEALKYLATED METABOLITE; AMNIOTIC-FLUID; FETAL EXPOSURE; ILLICIT DRUGS; HAIR; VALIDATION; URINE; METHADONE;
D O I
10.1016/j.forsciint.2009.04.005
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 ; 10 ;
摘要
A LCMS method was developed and validated for the simultaneous determination of buprenorphine (BUP), norbuprenorphine (NBUP), buprenorphine-glucuronide (BUP-Gluc) and norbuprenorphine-glucuronide (NBUP-Gluc) in human umbilical cord. Quantification was achieved by selected ion monitoring of precursor ions m/z 468.4 for BUP; 414.3 for NBUP; 644.4 for BUP-Gluc and 590 for NBUP-Gluc. BUP and NBUP were identified by MS', with m/z 396, 414 and 426 for BUP, and m/z 340, 364 and 382 for NBUP. Glucuronide conjugates were identified by MS3 with m/z 396 and 414 for BUP-Gluc and m/z 340 and 382 for NBUP-Gluc. The assay was linear 1-50 ng/g. Intra-day, inter-day and total assay imprecision (%RSD) were <14.5%, and analytical recovery ranged from 94.1% to 112.3% for all analytes. Extraction efficiencies were >66.3%, and process efficiency >73.4%. Matrix effect ranged, in absolute value, from 3.7% to 7.4% (CV < 2 1.8%, n = 8). The method was selective with no endogenous or exogenous interferences from 41 compounds evaluated. Sensitivity was high with limits of detection of 0.8 ng/g. In order to prove method applicability, an authentic umbilical cord obtained from an opioid-dependent pregnant woman receiving BUP pharmacotherapy was analyzed. Interestingly, BUP was not detected but concentrations of the other metabolites were NBUP-Gluc 13.4 ng/g, BUP-Gluc 3.5 ng/g and NBUP 1.2 ng/g. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:144 / 151
页数:8
相关论文
共 49 条
  • [11] Bioanalytical procedures for monitoring in utero drug exposure
    Gray, Teresa
    Huestis, Marilyn
    [J]. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2007, 388 (07) : 1455 - 1465
  • [12] Quantification of nicotine, cotinine, trans-3′-hydroxycotinine, nornicotine and norcotinine in human meconium by liquid chromatography/tandem mass spectrometry
    Gray, Teresa R.
    Shakleya, Diaa M.
    Huestis, Marilyn A.
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2008, 863 (01): : 107 - 114
  • [13] Buprenorphine and norbuprenorphine concentrations in human breast milk samples determined by liquid chromatography-tandem mass spectrometry
    Grimm, D
    Pauly, E
    Pöschl, J
    Linderkamp, O
    Skopp, G
    [J]. THERAPEUTIC DRUG MONITORING, 2005, 27 (04) : 526 - 530
  • [14] Rapid quantification of buprenorphine-glucuronide and norbuprenorphine-glucuronide in human urine by LC-MS-MS
    Hegstad, S.
    Khiabani, H. Z.
    Oiestad, E. L.
    Berg, T.
    Christophersen, A. S.
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 2007, 31 (04) : 214 - 219
  • [15] Determination of buprenorphine and norbuprenorphine in whole blood by liquid chromatography mass spectrometry
    Hoja, H
    Marquet, P
    Verneuil, B
    Lotfi, H
    Dupuy, JL
    Lachatre, G
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 1997, 21 (02) : 160 - 165
  • [16] The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry
    Huang, W
    Moody, DE
    McCance-Katz, EF
    [J]. THERAPEUTIC DRUG MONITORING, 2006, 28 (02) : 245 - 251
  • [17] Urinary buprenorphine concentrations in patients treated with Suboxone® as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay
    Hull, Mindy J.
    Bierer, Michael F.
    Griggs, David A.
    Long, William H.
    Nixon, Andrea L.
    Flood, James G.
    [J]. JOURNAL OF ANALYTICAL TOXICOLOGY, 2008, 32 (07) : 516 - 521
  • [18] Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome
    Jones, HE
    Johnson, RE
    Jasinski, DR
    O'Grady, KE
    Chisholm, CA
    Choo, RE
    Crocetti, M
    Dudas, R
    Harrow, C
    Huestis, MA
    Jansson, LM
    Lantz, M
    Lester, BM
    Milio, L
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2005, 79 (01) : 1 - 10
  • [19] Correlations of Maternal Buprenorphine Dose, Buprenorphine, and Metabolite Concentrations in Meconium With Neonatal Outcomes
    Kacinko, S. L.
    Jones, H. E.
    Johnson, R. E.
    Choo, R. E.
    Huestis, M. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (05) : 604 - 612
  • [20] Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of buprenorphine, norbuprenorphine, and metabolites in human urine
    Kacinko, Sherri L.
    Concheiro-Guisan, Marta
    Shakleya, Diaa M.
    Huestis, Marilyn A.
    [J]. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2008, 392 (05) : 903 - 911